Eruptive xanthomas associated with olanzapine use

Archives of Dermatology

Volumn 139, Issue 8, 2003, Pages 1045-1048

  Chang, Howard Y ^b   Ridhy, Todd W ^b   Kimball, Alexandra B ^b   Hughes, Elizabeth ^b   Oro, Anthony E ^a  

^a STANFORD UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BUSPIRONE; CHOLESTEROL; CITALOPRAM; CLOMIPRAMINE; DIPHENHYDRAMINE; FENOFIBRATE; FLUOXETINE; GABAPENTIN; GEMFIBROZIL; GLIBENCLAMIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SIMVASTATIN; TRIACYLGLYCEROL; TRIHEXYPHENIDYL;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DRUG INDUCED DISEASE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PUNCH BIOPSY; SKIN BIOPSY; SKIN DISEASE; XANTHOMA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PIRENZEPINE; SCHIZOPHRENIA; SKIN DISEASES; XANTHOMATOSIS;

EID: 0041520824     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.8.1045     Document Type: Article

References (34)

1. Goodnick PJ, Kato MM. Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin Pharmacother. 2001;2:1571-1582.
2. Kalinyak CM. Schizophrenia treatment: the use of atypical drugs - risperdal, zyperexa, and clozaril. Int J Psychiatr Nurs Res. 1998;4:445-451.
3. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med. 2001;52:503-517.
4. Masi G. Atypical neuroleptics in the treatment of early onset schizophrenia. Panminerva Med. 1997;39:215-221.
5. Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine. J Clin Psychiatry. 1998;59:687-689.
6. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001;62:15-26, 40-41.
7. Isakov I, Klesmer J, Masand PS. Insulin-resistant hyperglycemia induced by clozapine. Psychosomatics. 2000;41:373-374.
8. Kamran A, Doraiswamy PM, Jane JL, Hammett EB, Dunn L, Severe hyperglycemia associated with high doses of clozapine. Am J Psychiatry. 1994;151:1395.
9. Koller E, Schneider B, Bennett K, Dubitsky G, Clozapine-associated diabetes. Am J Med. 2001;111:716-723.
10. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;62:30-38.
11. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia, Int Clin Psychopharmacol. 2001;16:63-73.
12. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59-64.
13. Newcomer JW. Metabolic disturbances associated with antipsychotic use. J Clin Psychiatry. 2001;62(suppl 27):3-4, 40-41.
14. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337-345.
15. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol. 2001;11:25-32.
16. Popli AP, Konicki PE, Jurius GJ, Fuller MA, Jaskiw GE. Clozapine and associated diabetes mellitus. J Clin Psychiatry. 1997;58:108-111.
17. Ashcroft D, Frischer M, Lockett J, Chapman S. Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study. Pharmacoepidemiol Drug Saf. 2002;11:285-289.
18. Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation: clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs. 2001;15:351-359.
19. Gupta MA, Gupta AK. Olanzapine is effective in the management of some self-induced dermatoses: three case reports. Cutis. 2000;66:143-146.
20. Koo J, Lee CS. Delusions of parasitosis: a dermatologist's guide to diagnosis and treatment. Am J Clin Dermatol. 2001;2:285-290.
21. Tennyson H, Levine N. Neurotropic and psychotropic drugs in dermatology. Dermatol Clin. 2001;19:179-197.
22. Driscoll M, Rothe M, Grant-Kels J, Hale M. Delusional parasitosis: a dermatologic, psychiatric, and pharmacologic approach. J Am Acad Dermatol. 1993;29:1023-1033.
23. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171-176.
24. Avram AM, Patel V, Taylor HC, Kirwan JP, Kalhan S. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother. 2001;35:1381-1387.
25. Rigalleau V, Gatta B, Bonnaud S, et al. Diabetes as a result of atypical antipsychotic drugs: a report of three cases. Diabet Med. 2000;17:484-486.
26. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC, Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998;44:778-783.
27. Yazici KM, Erbas T, Yazici AH. The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes. 1998;106:475-477.
28. Feldman J. Glyburide: a second-generation sulfonylurea hypoglycemic agent: history, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. Pharmacotherapy. 1985;5:43-62.
29. Dicken CH, Connolly SM. Eruptive xanthomas associated with isotretinoin (13-cis-retinoic acid). Arch Dermatol. 1980;116:951-952.
30. Shelley WB, Rawnsley HM. Plasma cell granulomas in non-lipemic xanthomatosis: apparent induction by indomethacin. Acta Derm Venereol. 1975;55:489-492.
31. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160:2050-2056.
32. Luna B, Feinglos M. Drug-induced hyperglycemia. JAMA. 2001;286:1945-1948.
33. Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry. 2001;62:347-349.
34. Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther. 2002;24:21-37.